MedTrace Logo

Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan

NCT02977312 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 91

Last updated 2016-11-30

No results posted yet for this study

Summary

This study assessed the efficacy and safety of generic imatinib in patients with chronic myeloid leukemia (CML) in Jordan. It was a multicenter, non-interventional, open-label, prospective study combined with retrospective data collection from files of patients with a diagnosis of Ph+ CML, treated with Cemivil (imatinib), where no visits or intervention(s) additional to the daily practice were performed

Conditions

  • Chronic Myeloid Leukemia, Chronic Phase

Interventions

DRUG

Imatinib

Observation of chronic myeloid leukemia (CML) patients in chronic phase (CP) treated with Cemivil

Sponsors & Collaborators

  • Hikma Pharmaceuticals LLC

    lead INDUSTRY

Principal Investigators

  • Abdallah Abbadi, Professor · Jordan University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • Jordan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02977312 on ClinicalTrials.gov